Biomarkers offer data on vital health parameters and potential issues associated with diseases and disorders. Today, innovations in proteomics, genomics, bioinformatics, and metabolomics have accelerated the applications of biomarkers in identifying and validating systems. This accelerated growth has resulted in the advent of more precise tools and targeting systems. Such innovations have helped the biomedical and related industries by assisting drug development and disease management.
Robust solutions such as multiplex cytokine analysis and biomarker services have massive implications for the pharmaceutical and biotechnology sectors. Multiplex assay services offering bioanalytical solutions such as MSD and ELISA immunoassays are critical for accelerating biomarker-related applications such as cytokine assay services.
The current article shares the top trends in biomarker services that are impacting and influencing health care.
Vitality biomarkers
Historically, healthcare systems undertake a reactive approach to disease management and personal health. This approach poses significant obstacles in the early detection of diseases and personalized treatment for patients. Hence, companies and biomarker services are measuring or tracking the vitality of individuals to address these issues. By employing vitality biomarkers, clinicians can monitor the health status of individuals before symptoms emerge, enabling early therapeutic intervention and potential prevention of health problems.
Advanced imaging biomarkers
Traditional diagnostic methods are often time-consuming. During this long processing time, patients may undertake ineffective treatments, leading to potential side effects and unnecessary costs. However, advanced imaging biomarkers can monitor changes at the molecular or cellular levels and provide tangible information on disease regression or progression. One such example of advanced imaging biomarkers is diffusion-weighted imaging, where the tumor response is assessed against therapeutics by tracking the moment of water molecules.
Must Read: Optimizing Sample Preparation Techniques for LC-MS Analysis
Microbiome-based risk evaluations
The complexity of diseases and medical conditions makes it challenging to deliver the same treatment to different patient populations. Often, clinicians cannot provide personalized treatment because conventional methods do not account for the effects of individual microbiomes. Hence, healthcare organizations are incorporating microbial-based solutions to study the abundance, function, and diversity of microbial species. Such an approach helps generate unique data points about patients’ health status.
Translational biomarkers
Several discoveries in laboratories fail to reach the final clinical treatment stages. This delay results in unnecessary expenditures and delayed treatments. Today, translational biomarkers have shown results in preclinical and clinical research. Translational biomarker services can assess therapeutic efficacy across different drug development stages and thus increase the likelihood of successful clinical translation of ideas and solutions. Moreover, they can reduce the failure rates and uncertainty associated with transitioning research from labs to clinical settings.
Non-invasive biomarkers
Invasive monitoring and diagnostic procedures are stressful, painful, or may pose complications to the patient population. Hence, clinicians and drug developers face challenges with patient comfort and compliance. Invasive procedures may lead to less frequent monitoring, reduced patient cooperation, and reduced likelihood of early identification of health issues. Therefore, non-invasive biomarkers are gaining attention in biomedical and clinical settings. Non-invasive biomarkers can reveal health data without invasive procedures such as biopsies or blood draws. These biomarkers can be accessed easily from different sources such as saliva, urine, sweat, or even breath.
